Oprita Alexandru, Cotan Horia, Nitipir Cornelia
Oncology, Saint Nicholas Hospital, Pitesti, ROU.
Oncology, Elias Emergency University Hospital, Bucharest, ROU.
Cureus. 2024 Sep 1;16(9):e68380. doi: 10.7759/cureus.68380. eCollection 2024 Sep.
This study aims to examine the prognostic value of synchronous cancer diagnosis following an initial diagnosis of breast cancer, with a focus on site-specific survival rates and the correlation between primary breast cancer and secondary cancers.
We conducted a retrospective analysis of patients treated at Saint Nicholas Hospital in Pitesti, Romania, from January 2016 to January 2024. The inclusion criteria were a confirmed diagnosis of primary breast cancer and a secondary synchronous cancer diagnosed within two months. Data collection included demographic, clinical, and pathological characteristics, as well as treatment details and follow-up outcomes. Statistical analyses were performed using SPSS software version 26.0 (IBM Corp., Armonk, New York, USA), employing Kaplan-Meier survival curves, Cox regression models, and other relevant statistical tests.
Out of 73 initially identified patients, 49 met the inclusion criteria. The mean age was 59.6 years, with most patients being postmenopausal. Synchronous cancers were primarily contralateral breast cancer (44.9%) and female genital organ cancer (12.24%). Patients with synchronous bilateral breast cancer had significantly better overall survival (33 months) compared to those with other synchronous cancers (23.5 months). Multivariate analysis indicated that synchronous non-breast cancers were associated with a higher risk of death (hazard ratio (HR)=1.6, 95% CI: 1.22-2.10, p=0.003).
Synchronous cancer diagnosis following an initial breast cancer diagnosis significantly impacts prognosis, with synchronous bilateral breast cancer associated with better survival outcomes compared to other synchronous cancers. These findings underscore the importance of vigilant screening and personalized treatment strategies for patients with synchronous malignancies.
本研究旨在探讨乳腺癌初诊后同步癌症诊断的预后价值,重点关注特定部位的生存率以及原发性乳腺癌与继发性癌症之间的相关性。
我们对2016年1月至2024年1月在罗马尼亚皮特什蒂圣尼古拉斯医院接受治疗的患者进行了回顾性分析。纳入标准为确诊原发性乳腺癌且在两个月内诊断出继发性同步癌症。数据收集包括人口统计学、临床和病理特征,以及治疗细节和随访结果。使用SPSS 26.0软件(美国纽约州阿蒙克市IBM公司)进行统计分析,采用Kaplan-Meier生存曲线、Cox回归模型和其他相关统计检验。
在最初确定的73例患者中,49例符合纳入标准。平均年龄为59.6岁,大多数患者为绝经后。同步癌症主要为对侧乳腺癌(44.9%)和女性生殖器官癌症(12.24%)。同步双侧乳腺癌患者的总生存期(33个月)明显优于其他同步癌症患者(23.5个月)。多变量分析表明,同步非乳腺癌与更高的死亡风险相关(风险比(HR)=1.6,95%置信区间:1.22-2.10,p=0.003)。
乳腺癌初诊后同步癌症诊断对预后有显著影响,与其他同步癌症相比,同步双侧乳腺癌的生存结果更好。这些发现强调了对同步恶性肿瘤患者进行 vigilant筛查和个性化治疗策略的重要性。